#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

How do anti-SARS-CoV-2 IgG and IgM predict the titre of virus-neutralizing antibodies in donors of convalescent plasma against COVID-19 disease?


Authors: A. Entrová 1;  K. Azeem 2;  J. Vlčková 2;  J. Smital 1;  S. Zatloukalová 2;  J. Ševčíková 2;  H. Kollárová 2;  D. Horáková 2
Authors‘ workplace: Transfuzní oddělení, FN Olomouc 1;  Ústav veřejného zdravotnictví, LF UP, Olomouc 2
Published in: Transfuze Hematol. dnes,28, 2022, No. 4, p. 203-210.
Category: Original Papers
doi: https://doi.org/10.48095/cctahd2022203

Overview

Convalescent plasma was one of the treatment modalities in patients with severe or moderate course of the new acute respiratory disease COVID-19. The basic condition for its administration is a suffi cient virus neutralizing antibody titre ≥160. The aim of the present study is the analysis of the data of convalescent anti-covid plasma donors of the Transfusion Department of the Olomouc University Hospital, specifi cally to compare the correlation of serological tests of anti-SARS-CoV-2 antibodies with the virus neutralization test.

Keywords:

COVID-19 – convalescent plasma – anti-SARS-CoV-2 – VNT


Sources

1. Státní zdravotní ústav. Onemocnění novým koronavirem 2019-nCoV, nově pojmenovaným jako „COVID-19“ (coronavirus disease 2019). Praha: 2019. Dostupné z: http:/ / www. szu.cz/ uploads/ Epidemiologie/ Coronavirus/ Zakladni_ info/ 20200212_Onemocneni_novym_ koronavirem_2019.pdf.

2. Mezioborové stanovisko k podávání rekonvalescentní plazmy u pacientů s covid-19 (evidenční číslo ČSARIM: 18/ 2021).

3. European Commission Directorate-General For Health And Food Safety: An EU programme of COVID-19 convalescent plasma collection and transfusion: Guidance on collection, testing, processing, storage, distribution and monitored use. Brussels, 2021. Dostupné z: https:/ / ec. europa.eu/ health/ system/ files/ 2021-03/ guidance_ plasma_covid19_en_0.pdf.

4. Vyhláška č. 143/ 2008 Sb. Vyhláška o stanovení bližších požadavků pro zajištění jakosti a bezpečnosti lidské krve a jejích složek (vyhláška o lidské krvi)

5. Wendel S, Kutner JM, Machado R, et al. Screen ing for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program. Transfusion. 2021;60(12):2938–2951.

6. Wendel S, Fontao-Wendel R, Fachini R, et al. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibody kinetics: Proposals for better quality of CCP collections. Transfusion. 2021;61(5):1447–1460.

7. Zelená H. Testování neutralizačních protilátek proti SARS-CoV-2. Ostrava: 2020. Dostupné z: https:/ / zuova.cz/ Home/ Clanek/ testovani-neutralizacnich- protilatek-proti-covid.

8. Bohoněk M. Výroba a použití rekonvalescentní plazmy pro léčbu onemocnění COVID-19 v ČR – stručná informace. Transfuze Hematol Dnes. 2021;27(2):189–190.

9. Carter JA, Freedenberg AT, Romeiser JL, et al. Impact of serological and PCR testing requirements on the selection of COVID- 19 convalescent plasma donors. Transfusion. 2021;61(5):1461–1470.

10. Klein S, Pekosz A, Park HS, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 2020;130(11):6141–6150

11. Chvatal-Medina M, Mendez-Cortina Y, Patino PJ, Velilla PA, Rugeles MT. Antibody Responses in COVID-19: A Review. Front Immunol. 2021;12:633184.

12. Kallaste A, Kisand K, Aart A, Kisand K, Peterson P, Lember M. Antibody levels remain high to one-year‘s follow-up after moderate and severe COVID-19, but not after mild cases. Infect Dis (Lond). 2021;1–11.

13. Bläckberg A, Fernström N, Sarbrant E, Rasmussen M, Sunnerhagen T. Antibody kinetics and clinical course of COVID-19 a prospective observational study. PLoS One. 2021;16(3):e0248918.

14. Harvala H, Robb ML, Watkins N et al. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfus Med. 2021;31(3):167–175.

15. Benner SE, Patel EU, Laeyendecker O et al. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. J Infect Dis. 2020;222(12): 1974–1984.

16. Tiwari AK, Negi G, Jaiswal RM et al. Correlation of sample-to-cut-off ratio of anti-SARS- -CoV-2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multi-centric study in India. ISBT Sci Ser. 2021;16:269–275.

17. Mendrone-Junior A, Dinardo CL, Ferreira SC, et al. Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing. Transfusion. 2021;61(4):1181–1190.

Labels
Haematology Internal medicine Clinical oncology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#